Get started
Work

P3.18.08 Alectinib as Adjuvant Therapy in Resected ALK-Positive NSCLC: A Prospective Multicenter Cohort Study in China

Year: 2025
Type: article
Study design: Observational Study
DOI: 10.1016/j.jtho.2025.09.1024
Authors: C. Chen, C. Chen, D. Sun, D. Ge, F. Jiang, H. Liu, H. Tian, J. Hu, J. Zeng, N. Zhang, Q. Zhu, W. Wang, X. Cheng, Y. Zhang, Z. Peng, Y. Chen, Q. Zhang
Institutions: Tongji University, Shanghai Pulmonary Hospital, Union Hospital, Tianjin Chest Hospital, Fudan University, Zhongshan Hospital, Jiangsu Cancer Hospital, Liaoning Cancer Hospital & Institute, China Medical University, Shandong Provincial QianFoShan Hospital, Shandong First Medical University, First Affiliated Hospital Zhejiang University, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Tongji Hospital, Huazhong University of Science and Technology, Jiangsu Province Hospital, Central South University, Hunan Cancer Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Capital Medical University, Xuan Wu Hospital of the Capital Medical University, Shandong University, Shandong Provincial Hospital, Roche (China)
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4415520435
FWCI:
Cites:
Cited by:
Related to: 10